Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients

Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anders Vikerfors, Sabina Davidsson, Janusz Frey, Tomas Jerlström, Jessica Carlsson
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	urinary bladder cancer macroscopic hematuria soluble PD-L1 serum urine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8a2c402c2c944a3eaaf685f978113a8a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8a2c402c2c944a3eaaf685f978113a8a
record_format	dspace
spelling	oai:doaj.org-article:8a2c402c2c944a3eaaf685f978113a8a2021-11-25T17:04:37ZSoluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients10.3390/cancers132258412072-6694https://doaj.org/article/8a2c402c2c944a3eaaf685f978113a8a2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5841https://doaj.org/toc/2072-6694Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels (<i>p</i> = 0.038 and <i>p</i> = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease (<i>p</i> < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease (<i>p</i> = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC.Anders VikerforsSabina DavidssonJanusz FreyTomas JerlströmJessica CarlssonMDPI AGarticleurinary bladder cancermacroscopic hematuriasoluble PD-L1serumurineNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5841, p 5841 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	urinary bladder cancer macroscopic hematuria soluble PD-L1 serum urine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	urinary bladder cancer macroscopic hematuria soluble PD-L1 serum urine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anders Vikerfors Sabina Davidsson Janusz Frey Tomas Jerlström Jessica Carlsson Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
description	Soluble PD-L1 (sPD-L1) levels have been identified as a potential biomarker for various cancers, but its diagnostic and prognostic value in urinary bladder cancer (BC) remains to be fully elucidated. In this study, we investigated sPD-L1 levels in serum and urine samples from 132 patients with BC and compared them to 51 patients with hematuria (controls). The levels of sPD-L1 in serum and urine were determined using ELISA. Soluble PD-L1 could be detected in 99.5% of the serum samples and 34.4% of the urine samples. Patients diagnosed with BC had significantly higher urinary levels of sPD-L1, compared to controls, however no difference were found in serum sPD-L1 levels (<i>p</i> = 0.038 and <i>p</i> = 0.61, respectively). Significantly higher serum sPD-L1 levels were found in patients with muscle invasive disease and metastatic disease, compared to patients with non-muscle invasive BC and non-metastatic disease (<i>p</i> < 0.05). There was also a trend for higher urine sPD-L1 levels in patients with metastatic disease, compared to patients with non-metastatic disease (<i>p</i> = 0.05). The results from this study suggest that sPD-L1 in serum, but not in urine, could be a potential prognostic biomarker for patients with BC.
format	article
author	Anders Vikerfors Sabina Davidsson Janusz Frey Tomas Jerlström Jessica Carlsson
author_facet	Anders Vikerfors Sabina Davidsson Janusz Frey Tomas Jerlström Jessica Carlsson
author_sort	Anders Vikerfors
title	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_short	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_full	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_fullStr	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_full_unstemmed	Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients
title_sort	soluble pd-l1 in serum and urine in urinary bladder cancer patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8a2c402c2c944a3eaaf685f978113a8a
work_keys_str_mv	AT andersvikerfors solublepdl1inserumandurineinurinarybladdercancerpatients AT sabinadavidsson solublepdl1inserumandurineinurinarybladdercancerpatients AT januszfrey solublepdl1inserumandurineinurinarybladdercancerpatients AT tomasjerlstrom solublepdl1inserumandurineinurinarybladdercancerpatients AT jessicacarlsson solublepdl1inserumandurineinurinarybladdercancerpatients
_version_	1718412725782052864

Soluble PD-L1 in Serum and Urine in Urinary Bladder Cancer Patients

Ejemplares similares